泰格医药(03347)发布公告,预计2024年度营业收入约人民币60亿元–70亿元,比上年同期下降19%–5%;归属于上市公司股东的净利润约人民币3.8亿元–5.7亿元,比上年同期下降81%–72%;归属于上市公司股东的扣除非经常性损益后的净利润约人民币8.3亿元–10亿元,比上年同期下降44%–32%。
责任编辑:卢昱君
泰格医药(03347)发布公告,预计2024年度营业收入约人民币60亿元–70亿元,比上年同期下降19%–5%;归属于上市公司股东的净利润约人民币3.8亿元–5.7亿元,比上年同期下降81%–72%;归属于上市公司股东的扣除非经常性损益后的净利润约人民币8.3亿元–10亿元,比上年同期下降44%–32%。
责任编辑:卢昱君
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.